8legs: Kaist

Your Followed Topics

#1 out of 27.9K est. views10.00%

Rocket Lab will attempt the Bridging the Swarm launch of the Korean disaster-monitoring satellite NEONSAT-1A from New Zealand tonight after a prior delay.
The mission, Bridging the Swarm, will deploy NEONSAT-1A about 54 minutes after liftoff, placing it in low Earth orbit.
The NEONSAT program is funded by the Korean government and KAIST's SaTReC leads the system design and engineering.
NEONSAT-1A is designed to provide near-real-time natural disaster monitoring for the Korean peninsula with a high-resolution optical camera.
The launch will use Rocket Lab's Electron rocket and a kick stage to deploy the satellite into low Earth orbit.
Space.com will provide a live stream of the launch, available through Rocket Lab or Space.com’s coverage.
This will be Rocket Lab’s second launch of 2026 and its 81st mission overall, according to Space.com.
KAIST's SaTReC leads the mission's system design and engineering for NEONSAT.
The NEONSAT program is part of a broader collaboration among Korean academic, industry, and research institutions.
If successful, NEONSAT-1A will support near-real-time disaster monitoring for the Korean peninsula.

Vote 0

#2 out of 22.8K est. views

KAIST researchers reprogram tumor macrophages in situ using lipid nanoparticles to create enhanced CAR-macrophages inside the body.
Injected therapy leads macrophages to produce cancer-recognition proteins, transforming them into anticancer cells inside tumors.
Animal studies in melanoma showed slowed tumor growth and potential broader immune protection beyond the injected tumor.
The approach addresses delivery and immunosuppressive barriers that hinder current CAR-macrophage therapies.
The study was published in ACS Nano and led by KAIST researchers including Professor Ji-Ho Park.
The therapy relies on tumor-associated macrophages that naturally gather around tumors.
CAR-macrophages can directly engulf cancer cells and activate nearby immune responses.
The lipid nanoparticles carry both mRNA encoding cancer-recognition and an immune-boosting compound.
The KAIST team reports the therapy could broaden clinical applicability by avoiding cell extraction.
The research was funded by the National Research Foundation of Korea and presented by KAIST.

Vote 1

Unlimited Access

Personalized Feed

Full Experience

By continuing, you agree to the Privacy Policy.. You also agree to receive our newsletters, you can opt-out any time.

Create an account and enjoy content that interests you with your personalized feed

Unlimited Access

Personalized Feed

Full Experience

By continuing, you agree to the Privacy Policy.. You also agree to receive our newsletters, you can opt-out any time.